References

Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 2019

10.1016/s0140-6736(20)30925-9 · 2020 · External reference

Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver

10.1002/hep.27210 · 2014 · External reference

The Microbiota in Cirrhosis and Its Role in Hepatic Decompensation

10.1016/j.jhep.2020.11.013 · 2021 · External reference

10.3390/ijms26020527

10.3390/ijms26020527 · External reference

10.3389/fnut.2024.1337889

10.3389/fnut.2024.1337889 · External reference

10.1186/s12967‐025‐06774‐y

10.1186/s12967‐025‐06774‐y · External reference

The Gut‐Brain Axis

10.1146/annurev-med-042320-014032 · 2022 · External reference

Signals From the Gut Microbiota to Distant Organs in Physiology and Disease

10.1038/nm.4185 · 2016 · External reference

10.1016/j.phrs.2024.107361

10.1016/j.phrs.2024.107361 · External reference

Altered Serum Bile Acid Pattern as an Independent Factor for Covert and Overt Hepatic Encephalopathy in Patients With Cirrhosis

10.1111/hepr.70036 · 2026 · External reference

10.1016/j.jhepr.2022.100448

10.1016/j.jhepr.2022.100448 · External reference

Bile Acids and the Gut Microbiota: Metabolic Interactions and Impacts on Disease

10.1038/s41579-022-00805-x · 2023 · External reference

Bile Acid–Microbiota Crosstalk in Gastrointestinal Inflammation and Carcinogenesis

10.1038/nrgastro.2017.119 · 2018 · External reference

10.1080/21688370.2017.1373208

10.1080/21688370.2017.1373208 · External reference

A Gut–Brain Axis Regulating Glucose Metabolism Mediated by Bile Acids and Competitive Fibroblast Growth Factor Actions at the Hypothalamus

10.1016/j.molmet.2017.12.003 · 2018 · External reference

10.14814/phy2.13294

10.14814/phy2.13294 · External reference

Bile Acids in Hepatic Encephalopathy

10.1016/j.jceh.2018.04.011 · 2019 · External reference

FXR Agonists for MASH Therapy: Lessons and Perspectives From Obeticholic Acid

10.1002/med.21991 · 2024 · External reference

Fto Deficiency Reduces Anxiety‐ and Depression‐Like Behaviors in Mice via Alterations in Gut Microbiota

10.7150/thno.31562 · 2019 · External reference

Long Non‐Coding RNA ACTA2‐AS1 Promotes Ductular Reaction by Interacting With the p300/ELK1 Complex

10.1016/j.jhep.2021.12.014 · 2022 · External reference

Microglia Take Centre Stage in Neurodegenerative Disease

10.1038/s41577-018-0112-5 · 2019 · External reference

Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology

10.1007/s40265-018-1017-0 · 2019 · External reference

Microbiota Transplant for Hepatic Encephalopathy in Cirrhosis: The THEMATIC Trial

10.1016/j.jhep.2024.12.047 · 2025 · External reference

Microbiome Therapeutics for Hepatic Encephalopathy

10.1016/j.jhep.2021.08.004 · 2021 · External reference

The Microbiota–Gut–Brain Axis and Neurodevelopmental Disorders

10.1093/procel/pwad026 · 2023 · External reference

10.1016/j.bbadis.2024.167221

10.1016/j.bbadis.2024.167221 · External reference

10.1016/j.ab.2021.114436

10.1016/j.ab.2021.114436 · External reference

Farnesoid X Receptor Antagonizes Nuclear Factor κB in Hepatic Inflammatory Response

10.1002/hep.22519 · 2008 · External reference

Farnesoid X Receptor Activation Inhibits Inflammation and Preserves the Intestinal Barrier in Inflammatory Bowel Disease

10.1136/gut.2010.212159 · 2011 · External reference

FXR‐Mediated Regulation of eNOS Expression in Vascular Endothelial Cells

10.1093/cvr/cvm016 · 2008 · External reference

Regulation of Antibacterial Defense in the Small Intestine by the Nuclear Bile Acid Receptor

10.1073/pnas.0509592103 · 2006 · External reference

The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats

10.1016/j.ajpath.2014.10.009 · 2015 · External reference